Cancer Medicine最新文献

{"title":"Basal Marker ΔNp63α Is Enriched in Pancreatic Cancer Metastases but Not in Primary Tumors Post-Chemotherapy","authors":"Daniel H. Ryan,&nbsp;Yuuki Ohara,&nbsp;Michael J. Kruhlak,&nbsp;Xianyu Zhang,&nbsp;Miao Lin,&nbsp;Chin-Hsien Tai,&nbsp;Christine Alewine","doi":"10.1002/cam4.72322","DOIUrl":"10.1002/cam4.72322","url":null,"abstract":"<p>Cancer cells within a single pancreatic ductal adenocarcinoma (PDAC) are most often heterogeneous in their expression of the basal or classical transcriptional program. Predominance of the basal subtype has been associated with poorer patient outcomes and increased resistance to chemotherapy. Based on this, we predicted that basal subtype would be enriched in tumors previously treated with chemotherapy, and in metastases derived from primary PDAC tumors with a mixed basal/classical population. To create matched classical and basal cell lines, we stably transduced two classical PDAC cell lines (AsPC1 and HPAFII) with the basal program transcriptional driver ∆Np63α or an mCherry control and assessed their growth, metastasis, and response to chemotherapy both in vitro and in vivo. Forced expression of ∆Np63α successfully converted both cell lines to basal transcriptomic subtype, yet the basal program failed to drive increased cell growth or chemoresistance in culture and did not affect tumor growth of AsPC1 in the murine pancreas. In mice orthotopically engrafted with ∆Np63α-expressing cells, no statistically significant increase in spontaneous pulmonary metastases was observed for AsPC1 or HPAFII, however, pulmonary metastases were enriched for ∆Np63 expression as compared to established primary tumors, including expression of endogenous ∆Np63 in the mCherry control. Increased resistance to irinotecan chemotherapy was observed in ∆Np63α + HPAFII, yet treatment selected for ∆Np63-negative cells in both HPAFII and ASPC1. In summary, our data show that PDAC metastases are enriched for basal subtype, but chemotherapy treatment does not preferentially select for basal-type cells.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.72322","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Symptom Profiles Among Chinese Patients With Multiple Myeloma: A Latent Profile Analysis","authors":"Ting Wang,&nbsp;Yingying Lin,&nbsp;Leiwen Tang,&nbsp;Junxiang Sun,&nbsp;Weiwei Chen,&nbsp;Yanke Mao,&nbsp;Yao Ge,&nbsp;Huan Liu","doi":"10.1002/cam4.72312","DOIUrl":"10.1002/cam4.72312","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This cross-sectional study aimed to identify symptom profiles and their associated factors in Chinese patients with multiple myeloma, thereby providing an evidence-based foundation for developing targeted symptom management strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with multiple myeloma were recruited via convenience sampling from the hematology departments of three tertiary general hospitals in Zhejiang Province, China, between January and March 2024. Data collection utilized a sociodemographic and clinical characteristics questionnaire and the Chinese version of the M.D. Anderson Symptom Inventory-Multiple Myeloma Module (MDASI-MM) scale. The research conducted a latent profile analysis of symptom characteristics, followed by univariate analysis and multivariable multinomial logistic regression to examine factors associated with profile membership.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 265 Chinese patients with multiple myeloma. Latent profile analysis identified three distinct symptom profiles: “Low Symptom Burden with Walking Distress” (46.7%), “Moderate Physical Symptoms with Daily Life Interference” (37.9%), and “High Global Symptom Burden” (15.4%). Multinomial logistic regression analysis demonstrated that age, marital status, combination chemotherapy status, and Eastern Cooperative Oncology Group (ECOG) performance status were significantly associated with symptom profile membership (<i>p</i> &lt; 0.05). Specifically, patients of advanced age and those with higher ECOG scores were more likely to belong to the higher burden profiles, while patients receiving combination chemotherapy and those who were unmarried/divorced/widowed were more likely to belong to the low-burden profile.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with multiple myeloma exhibit heterogeneous symptom experiences, classifiable into three latent profiles. Our findings suggest that age, marital status, combination chemotherapy, and ECOG performance status may help identify patients at risk for higher symptom burden. Future longitudinal research is needed to evaluate whether profile-based interventions reduce symptom burden and improve quality of life.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13658839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dodonaea viscosa in Breast Cancer: Phytochemistry, Anticancer Mechanisms, and Emerging Immunotherapeutic and Translational Perspectives","authors":"Nireshini Reddy,&nbsp;Catherine H. Kaschula,&nbsp;Nokwanda P. Makunga,&nbsp;Willem Jacobus Perold,&nbsp;Sanjeev Rambharose,&nbsp;Anna-Mart Engelbrecht","doi":"10.1002/cam4.72240","DOIUrl":"10.1002/cam4.72240","url":null,"abstract":"<p>Breast cancer remains a leading cause of cancer-related mortality among women worldwide, with treatment resistance, disease heterogeneity, and therapy-associated toxicities limiting clinical outcomes. Its major clinically relevant subtypes, including oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer (TNBC), differ substantially in their molecular characteristics, therapeutic targets, and treatment responses. Consequently, there is growing interest in naturally derived compounds that modulate multiple pathways involved in tumour progression and therapeutic response. <i>Dodonaea viscosa</i> has attracted attention because of its diverse phytochemical composition and anticancer activity. However, the contribution of its flavonoid constituents to breast cancer biology and their relevance to emerging immunotherapeutic approaches have not been comprehensively synthesized. This review critically evaluates the anticancer activity of flavonoids identified in <i>D. viscosa</i>, with emphasis on quercetin, kaempferol, and rutin. These compounds exhibit antioxidant, anti-inflammatory, antiproliferative, pro-apoptotic, and anti-angiogenic activities through modulation of targets implicated in breast cancer progression, including cyclooxygenase-2 (COX-2), NADPH oxidase (NOX) enzymes, vascular endothelial growth factor (VEGF), and signalling pathways associated with tumour growth, metastasis, and immune regulation. Emerging evidence also suggests that they may influence tumour-immune interactions and immune checkpoint pathways relevant to programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), highlighting potential immunotherapeutic relevance. By integrating current evidence on the phytochemistry, molecular mechanisms, and immunomodulatory properties of <i>D. viscosa</i>-derived flavonoids, this review provides a mechanistic and translational framework linking chemical composition to reported anticancer activity. The review identifies key gaps in mechanistic validation, pharmacokinetics, bioavailability, and clinical translation, and proposes future research priorities for evaluating <i>D. viscosa</i>-derived flavonoids as adjunctive candidates in breast cancer immunotherapy and precision oncology.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.72240","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vivo Immunoscoring Technique to Monitor Anti-CD47 Immunotherapy Efficacy in Triple-Negative Breast Cancer","authors":"Minfeng Yang,&nbsp;Shiqiang Hou,&nbsp;Chi Ming Wong,&nbsp;Hongzhao Chen,&nbsp;Chunjin Jin,&nbsp;Song-Bai Liu,&nbsp;Jung Sun Yoo","doi":"10.1002/cam4.72232","DOIUrl":"10.1002/cam4.72232","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Phagocytosis checkpoints, such as CD47, have emerged as promising targets for cancer immunotherapy and are being investigated in clinical trials. Despite encouraging findings, reliable biomarkers for monitoring immunotherapeutic responses in triple-negative breast cancer (TNBC) remain tracking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this project is to characterize the functional states of tumor-associated macrophages (TAMs) using macrophage-related imaging probes and assess their potential for monitoring responses to anti-CD47 immunotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Anatomical imaging visualized tumor nodule formation and angiogenesis in tumor-bearing mice. Conventional fluorescence imaging demonstrated the TNBC-targeting ability of monocyte chemoattractant protein-1 (MCP-1) fluorescein isothiocyanate (FITC) and Dextran-Alexa Fluor 680 (AF 680). Intravital imaging elucidated the pharmacokinetics of the imaging probes in TAMs following intravenous injection. These probes preferentially targeted macrophages, as confirmed by the colocalization between F4/80-, CD86-, and CD206-binding cells and imaging probe-targeted cells. Tumor-bearing mice that received intravenous injections of the imaging probes were sacrificed, and the TNBC tissue was cryo-sectioned, stained, and imaged on a confocal microscope, showing a high molecular targeting ability of the imaging probes for macrophages. The M1/M2 macrophage ratio was quantified for monitoring the response to anti-CD47 immunotherapy, which demonstrated that MCP-1 and Dextran are useful tools for M1 and M2 macrophage identification.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study documents a molecularly targeted construct for TAMs in vivo and verifies proof of the utility of using the M1/M2 ratio as a strategy for monitoring the response to CD47 treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.72232","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-Year Survival Analyses on Non-Pathological Complete Response Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Regimens Plus Surgery: A Propensity Score Matching, Real-World Cohort Study","authors":"Weibin Liu,&nbsp;Yujie Deng,&nbsp;Yan Lin,&nbsp;Yijin Lin,&nbsp;Xuejin Zheng,&nbsp;Weikun Su,&nbsp;Weijin Xiao,&nbsp;Yi Shi,&nbsp;Jiarong Zhang,&nbsp;Xiaohui Chen","doi":"10.1002/cam4.72260","DOIUrl":"10.1002/cam4.72260","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Non-pathological complete response (non-pCR) is common in esophageal squamous cell carcinoma (ESCC) patients after neoadjuvant therapy, yet evidence guiding long-term outcomes and postoperative risk stratification in the immunotherapy era remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively enrolled consecutive ESCC patients treated with neoadjuvant immunochemotherapy (nICT) or chemotherapy alone (nCT) followed by esophagectomy and restricted analyses to non-pCR cases. Primary endpoints were five-year overall survival (OS) and event-free survival (EFS). A 1:1 optimal propensity score matching (PSM) procedure and administrative censoring at 60 months were applied. Survival outcomes were assessed using Kaplan–Meier and Cox proportional hazards analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 366 patients with non-pCR disease, 164 matched pairs were generated. After matching, nICT demonstrated a higher major pathological response (MPR) rate (19.5% vs. 6.1%), a lower ypT4 proportion (3.7% vs. 22.0%), and fewer recurrence/metastasis rate (40.2% vs. 58.5%), all <i>p</i> &lt; 0.001. In the matched multivariable Cox model, nICT was independently associated with a lower risk of EFS events (HR 0.55, 95% CI 0.36–0.84; <i>p</i> = 0.005), whereas no independent association with OS was observed (HR 0.94, 95% CI 0.70–1.27; <i>p</i> = 0.707). Open esophagectomy (OE), ypN2-3 disease, and perineural invasion (PNI) were associated with worse EFS, whereas lower Ki-67 expression and postoperative adjuvant treatment were associated with better EFS. PNI was associated with worse OS, and postoperative adjuvant treatment was associated with better OS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Among non-pCR ESCC patients after neoadjuvant therapy and surgery, nICT was associated with lower recurrence risk and improved five-year EFS compared with nCT, whereas a significant OS advantage was not observed. Pathological factors (PNI, high Ki-67, and residual nodal burden) and postoperative treatment may help inform risk stratification, although the observational treatment associations should be interpreted cautiously.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13642975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding “Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase”","authors":"Maria Mazzitelli,&nbsp;Pierluigi Del Vecchio,&nbsp;Jon Salmanton-García,&nbsp;Antonella Cingolani,&nbsp;Livio Pagano,&nbsp;Carlo Torti","doi":"10.1002/cam4.72327","DOIUrl":"10.1002/cam4.72327","url":null,"abstract":"&lt;p&gt;We read with interest the recent article by Caracciolo et al. [&lt;span&gt;1&lt;/span&gt;] evaluating the outcomes of patients with hematologic cancers and COVID-19 during the late pandemic phase. While we appreciate the authors' effort to provide real-world data in this particularly vulnerable population, we believe that the study conclusions are significantly limited by the omission of a crucial determinant of clinical outcome: the impact of COVID-19 treatment strategies that were progressively implemented and recommended by the Italian Drug Agency.&lt;/p&gt;&lt;p&gt;Indeed, the authors presented a detailed analysis of demographics, malignancy type, vaccination status, and outcomes, but failed to account for the role of antiviral agents, monoclonal antibodies, corticosteroids, and other immunomodulatory therapies. These interventions, whether administered during the early phase of the infection or in the advanced disease, may substantially influence patient prognosis. The decision to not include such information represents a major limitation, as several studies clearly demonstrated that treatment availability and timing are critical determinants of survival and morbidity among patients with hematologic malignancies and SARS-CoV-2 infection.&lt;/p&gt;&lt;p&gt;In particular, several studies [&lt;span&gt;2-4&lt;/span&gt;] have shown that early administration of antiviral and targeted therapies significantly improves clinical outcomes and reduces mortality in this high-risk population. Moreover, other investigations [&lt;span&gt;5, 6&lt;/span&gt;], demonstrated the beneficial impact of antiviral agents, either alone or in combined regimens, in patients with severe immunosuppression and hematological cancers. Failing to consider treatment administration as key variables may have introduced substantial bias into the analysis, especially considering that 2022–2023 was a period characterized by wide availability of effective therapeutic agents, including remdesivir and nirmatrelvir/ritonavir [&lt;span&gt;7&lt;/span&gt;]. Moreover, given the variable efficacy of certain treatments, particularly monoclonal antibodies against different SARS-CoV-2 variants, individual therapeutic strategies may have significantly influenced the outcomes assessed in this study and should therefore be explicitly reported.&lt;/p&gt;&lt;p&gt;Without stratification according to the possible COVID-19 treatment received, it is difficult to determine whether the observed mortality rates are attributable primarily to the underlying hematologic malignancies, to inadequate immune protection post-vaccination, or to differences in the therapeutic management. Furthermore, given that treatment approaches evolved substantially during the late pandemic phase, their exclusion represents an important methodological limitation that weakens the reliability of the conclusions. In particular, it would be misleading to attribute the decrease in mortality solely to a lower virulence of SARS-CoV-2. Such an interpretation could inadvertently lead both clinicians and patients to ","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter by Mazzitelli M. et al. Regarding “Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase”","authors":"Daniele Caracciolo,&nbsp;Pierfrancesco Tassone,&nbsp;Pierosandro Tagliaferri","doi":"10.1002/cam4.72326","DOIUrl":"10.1002/cam4.72326","url":null,"abstract":"&lt;p&gt;We read with great interest the letter by Mazzitelli et al. [&lt;span&gt;1&lt;/span&gt;] regarding our study on the impact of COVID-19 in patients with hematologic malignancies during the late pandemic phase. The authors emphasize the omission of early antiviral treatments and monoclonal antibodies (mAbs) as confounding factors in our analysis. We welcome the opportunity to clarify our methodological choices and provide further insights based on our broader clinical experience.&lt;/p&gt;&lt;p&gt;First, we agree that the therapeutic landscape has evolved significantly. However, our study was designed to reflect the epidemiology and intrinsic risk factors of hematological patients, following the framework of landmark cohorts in the field. Large-scale studies, such as the ITA-HEMA-COV registry [&lt;span&gt;2&lt;/span&gt;] and the EPICOVIDEHA reports [&lt;span&gt;3&lt;/span&gt;], have consistently highlighted the type and status of the underlying malignancy (e.g., active/progressive disease, acute myeloid leukemia, or specific lymphoproliferative subtypes) and the patient's immune status as independent risk factors for severe outcomes. We agree that COVID-19-directed therapies represent an important component of the clinical context and that systematic information on their type and timing would have provided additional information for interpreting our findings. However, our analysis was specifically designed to characterize the clinical course and outcomes of COVID-19 infection in this population, with particular emphasis on patient- and disease-related prognostic factors, rather than to evaluate the efficacy or causal contribution of individual antiviral or monoclonal antibody treatments. Granular data on antiviral or monoclonal antibody regimens administered during acute infection were therefore not systematically collected. We acknowledge this as a limitation of our dataset. At the same time, we do not believe that the absence of treatment-specific data compromises the validity of the prognostic associations and therefore the conclusions of our study.&lt;/p&gt;&lt;p&gt;Moving forward, capturing this information in a systematic manner will be crucial, now that SARS-CoV-2 is best considered alongside other endemic respiratory pathogens in hematologic patients, and we welcome the opportunity to collaborate with colleagues, including the authors of this letter, on future studies integrating systematic respiratory-infection surveillance with therapeutic stratification in this population.&lt;/p&gt;&lt;p&gt;Second, this letter allows us to further emphasize the important role of antiviral strategies, particularly in the setting of pre-exposure prophylaxis (PrEP) [&lt;span&gt;4&lt;/span&gt;], while firmly rejecting any assertion that COVID-19 should be underestimated due to perceived reduced virulence. We agree that the decline in mortality observed over the study period should not be attributed solely to changes in SARS-CoV-2 virulence. At the same time, in the absence of treatment-specific data, it would be equally inappropriate to ","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13640057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of First-Line Treatment Options for Oncogene Wild-Type Lung Adenocarcinoma With Liver Metastases","authors":"Jie Li,&nbsp;Yihui Ge,&nbsp;Qiaohong Liu,&nbsp;Xiaojuan Wei,&nbsp;Jian Wang,&nbsp;Xiufen Wang,&nbsp;Dahai Wang,&nbsp;Jiannan Liu,&nbsp;Yuping Sun,&nbsp;Aiqin Gao","doi":"10.1002/cam4.72282","DOIUrl":"10.1002/cam4.72282","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Liver metastasis represents one of the frequent drivers for cancer-related mortality in lung adenocarcinoma. For advanced lung adenocarcinoma harboring wild-type oncogene drivers, chemotherapies in combination with immune checkpoint inhibitors (ICIs) and/or bevacizumab (named IC, BC, and IBC, respectively) are alternative first-line schemes as recommended by canonical treatment guidelines. However, due to the immunosuppressive tumor microenvironment in the liver, patients with liver metastases are less effective to ICIs. For this subpopulation, the optimal regimen is still undetermined.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this retrospective multicenter cohort study, treatment-naïve lung adenocarcinoma patients with wild-type oncogene drivers and liver metastases were enrolled from 4 cancer centers between January 2018 and December 2023. All these patients received BC, IC, or IBC as the first-line therapies. Propensity Score Matching (PSM) was applied to balance baseline covariates. Kaplan-Meier survival analysis, log-rank tests, and Cox proportional-hazards regression were used to compare PFS and OS among groups.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 191 Patients were enrolled, in which 70 (36.6%) received IC treatment, 70 (36.6%) received BC and 51 (26.7%) received IBC treatment. After PSM, 135 eligible patients were selected, including 45 Patients in each group. IBC group showed a slightly higher ORR (44.4%) and significantly higher DCR (95.6%, &lt;i&gt;p&lt;/i&gt; = 0.013) compared with BC (ORR = 37.2%, DCR = 81.4%) and IC (ORR = 38.5%, DCR = 71.8%) groups, as evaluated by the primary lung lesions. When liver metastases were used as target lesions, similar response was observed. The median progression-free survival (mPFS) in patients receiving IBC (8.48 months, 95% CI: 5.98–16.10 months) was significantly longer than those receiving BC (5.09 months, 95% CI: 3.55–7.46 months) and IC (4.86 months, 95% CI: 3.06–7.82 months) (IBC vs. BC: HR = 0.477, 95% CI: 0.295–0.772, &lt;i&gt;p&lt;/i&gt; = 0.002; IBC vs. IC: HR = 0.479, 95% CI: 0.292–0.784, &lt;i&gt;p&lt;/i&gt; = 0.003). IBC also showed a numerically longer OS than IC (18.99 months vs. 12.52 months; HR = 0.692, 95% CI: 0.429–1.114, &lt;i&gt;p&lt;/i&gt; = 0.128), although this difference did not reach statistical significance. Subgroup analyses, conducted as pre-specified exploratory analyses, showed that patients with male gender, smoking history, brain metastasis, polymetastases and low PD-L1 expression (&lt; 50%) displayed superior PFS when treated with IBC compared with their counterparts. Besides, IBC showed comparable adverse events relative to IC and BC treatments.&lt;/p","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Diagnosis, Treatment, and Prognosis of Adult Pancreatoblastoma\".","authors":"","doi":"10.1002/cam4.72345","DOIUrl":"10.1002/cam4.72345","url":null,"abstract":"","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":"e72345"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149072784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Metronomic Chemotherapy in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Multicenter Study.","authors":"Lara Laini, Deborah Cosentini, Marta Laganà, Salvatore Grisanti, Giulia Scartabellati, Gianluca Fogazzi, Salvatore Strazzeri, Vito Amoroso, Greta Schivardi, Rebecca Pedersini, Alfredo Berruti, Antonella Turla","doi":"10.1002/cam4.72325","DOIUrl":"10.1002/cam4.72325","url":null,"abstract":"<p><strong>Purpose: </strong>The optimal chemotherapy strategy after progression on cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer remains a matter of controversy. This study evaluated the efficacy of metronomic chemotherapy compared with other post-CDK4/6i treatment strategies in a real-world setting.</p><p><strong>Patients and methods: </strong>This retrospective multicenter study included patients with HR+/HER2- metastatic breast cancer progressing on CDK4/6i plus endocrine therapy and subsequently treated with systemic therapy. Progression-free survival (PFS) was the primary endpoint. Secondary endpoints included overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), and safety. Propensity score matching (1:2) was performed to reduce selection bias.</p><p><strong>Results: </strong>A total of 177 patients were included, of whom 52 (29.4%) received metronomic chemotherapy. Among treatment strategies, metronomic chemotherapy achieved the longest median PFS (9 months; 95% CI: 5.46-12.53; p = 0.003). In multivariable analysis, metronomic chemotherapy was independently associated with prolonged PFS (HR 0.46, 95% CI: 0.30-0.69; p < 0.001). Median OS did not significantly differ across treatment groups. ORR was 48.0%, and CBR was 60.0% with metronomic chemotherapy. After propensity score matching, metronomic chemotherapy maintained a significant association with improved PFS (HR 0.49, 95% CI: 0.31-0.78; p = 0.003). Toxicities were predominantly Grade 1-2, with no severe adverse events reported in the metronomic cohort.</p><p><strong>Conclusion: </strong>In this real-world study, metronomic chemotherapy was associated with improved disease control and a favorable safety profile in patients with HR+/HER2- metastatic breast cancer progressing after CDK4/6i-based therapy.</p><p><strong>Trial registration: </strong>Protocol Number 0037558/23.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":"e72325"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}